AI-designed GIPC1 inhibitor shows promising results against pancreatic cancer

Researchers used artificial intelligence to design an inhibitor of the GIPC1 protein and tested it across several preclinical models of pancreatic ductal adenocarcinoma. The results were described as highly promising. However, scientists caution that the path from preclinical success to a working human therapy remains long and uncertain.